Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops a drug-device therapy for the treatment of pain.
Year Established: | |
Funding: | |
Address: | 575 Chesapeake Drive |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 650-216-6500 |
Mail: | info@acelrx.com |
Company URL: | http://www.acelrx.com |
Careers
AcelRx welcomes you to apply for open positions.
AcelRx is currently accepting resumes and is actively recruiting for the following positions:
We do not have any openings at this time.
Please send resume to: info@acelrx.com
Alta Partners,Three Arch Partners
Richard King, President & CEO
Prior to joining AcelRx in 2010, Mr. King was Chief Operating Officer of Tercica. Prior to Tercica, he served as Executive Vice President, Commercial Operations of Kos Pharmaceuticals, Inc. from 2002 to 2006. At Kos, he was responsible for sales, marketing, managed care, sales operations and customer service functions. Under Mr. King’s commercial leadership, Kos realized revenue growth from $90 million to approximately $750 million. Kos attained profitability in 2003, and the commercial success resulted in the Abbott acquisition of Kos in 2006. From 2000 to 2002, Mr. King was Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. From 1992 to 2000, and from 1988 to 1992, Mr. King held various marketing positions at SmithKline Beecham Pharmaceuticals and Lederle Laboratories Ltd, respectively. Richards holds a BSc in Chemical Engineering from University of Surrey and an MBA in Marketing from Manchester Business School.
Pamela P. Palmer, MD, PhD, Chief Medical Officer & Co-Founder
In addition to her role as the CMO for AcelRx, Dr. Palmer recently stepped down from her position as Professor of Anesthesia and Perioperative Care at the University of California, San Francisco and Director of UCSF PainCARE - Center for Advanced Research and Education - to focus full-time on her duties at AcelRx. Dr. Palmer continues on as a volunteer faculty member at UCSF specializing clinically in treating acute and chronic pain. Dr. Palmer received her MD from Stanford University and her PhD from the Stanford Department of Neuroscience. Dr. Palmer is also a co-founder of Omeros Medical Systems, Inc. and remains involved as a consultant in the company’s ongoing research efforts.
Larry G. Hamel, Chief Development Officer
Larry brings 28 years of experience in pharmaceutical development with primary focus on development of oral drug delivery systems. Since 1986, Larry has personally managed or directed 43 IND submissions and 8 new NDA submissions from inception through commercialization. He brings a thorough understanding of the Regulatory and Development processes in both the US and EU. During his tenure at ALZA, Larry brought a number of new technologies to commercial readiness, including Push-Stick and patterned delivery designs. Larry holds a BS in Biology from the University of Michigan.
Anil Dasu, Chief Engineering Officer
Anil joined AcelRx in September 2007 from Anesiva Inc., where he most recently served as Vice President of Medical Device Engineering. At Anesiva, Anil was responsible for all medical device development leading to a New Drug Application (NDA) approval for Zingo ™, a combination drug-device product indicated for the reduction of pain associated with needlesticks and cannula placements in pediatric patients. Prior to Anesiva, Anil was Vice President for Manufacturing and Device Development at AlgoRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing products to treat pain. At AlgoRx, Anil had broad responsibility for clinical supplies manufacturing, facilities, supply chain management as well as device development. Prior to AlgoRx, Anil was with PowderJect Pharmaceuticals, where he served as Vice President of Manufacturing and Process Development. Previously, Anil served in various capacities in process development at Metrika, Inc. and Cygnus, Inc. He holds a BE degree in Chemical Engineering from the University of Mangalore, India and MS degree in Chemical Engineering from the University of Tulsa and is a member of AAMI.
Carter J. King, Vice President, Finance
Carter joined AcelRx in early 2006 as one of the first employees. Carter brings over 15 years of finance and operations experience in pharmaceuticals, biotechnology and healthcare services. Immediately prior to AcelRx Carter led the strategic planning and portfolio management efforts at ALZA Corporation, a Johnson & Johnson company. Prior to ALZA, Carter held a number of positions at Coulter Pharmaceutical/Corixa Corporation, ultimately as Director of Finance where he was responsible for finance, accounting and operations as well as financial management of the corporate partnership with GlaxoSmithKline. While at Coulter/Corixa, Carter also helped develop the systems and infrastructure necessary to launch the company’s first product, Bexxar® which was subsequently acquired by GSK. Carter began his career at GATX Capital providing finance and accounting support across a broad range of leasing and capital investments. He holds a BA in Business Economics from UC Santa Barbara and an MBA from the Haas School of Business at UC Berkeley.
Linda Judge, Vice President, Intellectual Property
Linda brings over 15 years of experience in intellectual property law practice covering all aspects of patent matters, and the drafting and negotiating of license, development, clinical and related transactional agreements in both the law firm and in-house setting. Linda most recently was a partner in the Intellectual Property law practice of DLA Piper US LLP and prior to that was Director of Intellectual Property at Cell Genesys, Inc., a cancer therapeutics company. She has worked with small and large pharmaceutical and biotechnology companies as well as with academic institutions. Linda has experience in the fields of pharmaceuticals, biotechnology, medical devices and related biological and chemical systems. Linda also brings over 10 years scientific experience in the laboratory setting as both a bench scientist and in a supervisory capacity. Linda has a J.D. from Santa Clara University, and an M.S. in Environmental Chemistry. She is admitted to practice law in California and is a registered Patent Attorney before the US Patent & Trademark Office.
Mark A. Evashenk, Vice President, Clinical Operations
Mark has over 25 years of pharmaceutical and device development experience with a focus on project management and clinical operations. Prior to joining AcelRx, Mark was Director of Clinical Operations at ALZA Corporation, a Johnson & Johnson Company. Throughout his career he managed 2 NDA filings and helped lead a clinical operations team for 2 additional NDA submissions, all of which resulted in commercial launches. He has managed clinical operations teams for well over 100 phase I studies, including over 10 first in man, and numerous phase II, III and IIIB studies. Mark has managed studies in the US, Canada, Western Europe and Eastern Europe, India and Australia. Mark holds his BS degree in Environmental Toxicology from UC Davis.
Nigel Ray, MBA, Vice President, Business Development
Nigel Ray leads AcelRx Pharmaceuticals business development and partnering activities as Vice President of Business Development. Nigel has over 20 years of experience in the pharmaceutical industry in a variety of business development, sales and marketing, and general management roles. Nigel joined AcelRx in 2009 from Limerick BioPharma where he was Vice President of Business Development. Prior to Limerick, Nigel led business development at DURECT Corporation where he negotiated several significant licensing transactions, including a late 2008 transaction with Alpharma, Inc. for the rights to ELADUR, a transdermal pain product. Previously, Nigel served in a variety of marketing and business roles for ALZA Corporation. Nigel began his career at DNAX Research Institute. He holds a BA in Human Biology from Stanford University and an MBA with academic distinction from UCLA's Anderson School of Business.